Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35566668/
Our findings indicate that treatment with PCSK9 inhibitors has a multipotential effect on fibrinolysis and coagulation in patients with isolated hypercholesterolemia and that this medication may have some future benefits...
Conclusion: Our findings indicate that treatment with PCSK9 inhibitors has a multipotential effect on fibrinolysis and coagulation in patients with isolated hypercholesterolemia and that this medication may have some future benefits in patients who are statin-intolerant or contraindicated to statin use.
Share
-
Dr Hamid3yrThe purpose of this trial was to determine the efficacy of PCSK9 inhibitors alone in patients with isolated hypercholesterolemia and will help in treatment of patients
PCSK9 Inhibitors
Source : https://www.ncbi.nlm.nih.gov/books/NBK448100/
Familial hypercholesterolemia is characterized by extremely high total and LDL cholesterol levels, premature vascular disease, and tendon xanthomas. In most cases, this is due to a genetic mutation of the...
Relevance: This activity outlines the indications, mechanism of action, administration methods, significant adverse effects, contraindications, monitoring, and toxicity of PCSK9 inhibitors so providers can direct patient therapy to optimal outcomes in serum lipid management with these agents and obtain improved cardiovascular outcomes.
Share
Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Source : https://www.clinicaltherapeutics.com/article/S0149-2918(22)00149-7/fulltext
Despite the widespread use of evidence-based cardiovascular treatments, patients with acute coronary syndrome (ACS) remain at high risk for ischemic cardiovascular events.1-3 This risk is partly caused by elevated LDL-C...
Implications: Among Chinese patients who underwent PCI for ACS, the early initiation of evolocumab combined with statin treatment effectively reduced LDL-C levels and lowered the incidence of recurrent ischemic cardiovascular events, with satisfactory tolerability and safety. Chinese Clinical Trial Registry identifier:
Share
Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study
Source : https://www.sciencedirect.com/science/article/abs/pii/S0896841122000403?via=ihub
The proprotein convertase subtilisin/kexin type 9 (PCSK9) is emerging as a novel cardiovascular risk factor. Levels of PCSK9 in thrombotic primary ant...
Conclusion: These preliminary data suggest that PCSK9 levels are increased in PAPS patients with arterial and recurrent thrombosis. Its role as a possible therapeutic target in PAPS needs further studies.
Share
Low-Density Lipoprotein Cholesterol Levels in Coronary Artery Disease Patients: Opportunities for Improvement
Source : https://www.hindawi.com/journals/crp/2022/7537510/
Background . We sought to characterize the level of LDL-C control and identify opportunities for improvement and characteristics of patients who were undertreated. Methods . Study patients were from a...
Conclusions: There were important variations in LDL-C control between patients in our health system with the same indication for treatment. Variation in treatment among physicians is an area ripe for quality improvement interventions. This study may be easily reproduced by other medical centers and used for highlighting both patient and...
Share